




| | | | |
|--|--|----------------------------|--------------------------|
| <p>INFORMATION DISCLOSURE STATEMENT Form PTO-1449</p> | | Application Details | |
| | | First Named Inventor | Daniel Mark Hickinson |
| | | Filing Date | Herewith |
| | | Application Serial No. | Not yet assigned |
| | | Examiner Name | Not yet assigned |
| | | Group Art Unit | Not yet assigned |
| | | Attorney Docket No. | 100873-1P US |

| U.S. PATENT DOCUMENTS | | | | | | | |
|---|-----------|-----------------|------------------|------|-------|-----------|----------------------------|
| Examiner Initials | Desig. ID | Document Number | Publication Date | Name | Class | Sub Class | Filing Date if Appropriate |
|  | AA | US 5 804 396 A | 8 September 1998 | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|---|-----------|-----------------|------------------|--------------------------|-------|-----------|-------------|------------------|
| Examiner Initials | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Sub Class | Filing Date | English Language |
| | | | | | | | | Y |
|  | AB | WO 02 09684 A | 7 February 2002 | | | | | Y |
|  | AC | WO 02 41828 A | 30 May 2002 | | | | | Y |
|  | AD | WO 03 061559 A | 31 July 2003 | | | | | Y |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |




| OTHER DOCUMENTS (include Author, Title, Date and Place of Publication) | | | |
|---|-----------|--|--|
| Examiner Initials | Desig. ID | Document | |
|  | AE | RAM G ET AL : "Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification" Cell Growth And Differentiation, vol. 11, no. 3, March 2000 (2000-03), pages 173-183. | |


| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 11/15/06 |
|--------------------|---|-----------------|----------|

*EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/532152
JC13 Rec'd PCT/PTO 20 APR 2005

Sheet 2 of 2

| | | |
|---|----|---|
|  | AF | RAM ET AL : "Phosphatidylinositol 3-kinase recruitment by p185-erb-2 and erb-3 is potently induced by neu differentiation factor/hereregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erb-2 gene amplification" cell growth and differentiation, The Association, Philadelphia, PA, US, vol . 7, no . 5, May 1996 (1996-05), pages 551-561. |
|  | AG | RAM ET AL : "Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185-erbalpha-B-2" Molecular Carcinogenesis, vol . 15, no . 3, 1996, pages 227-238. |
|  | AH | RAM ET AL : "Hereregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells" Journal Of Cellular Physiology, vol . 183, no . 3, June 2000 (2000-06), pages 301-313. |
|  | AI | LEWIS ET AL : "Growth regulation of human breast and ovarian tumor cells by hereregulin : evidence for the requirement of erbB2 as a critical component in mediating hereregulin responsiveness" Cancer Research, American Association For Cancer Research, Baltimore, MD, US, vol . 56, 15 March 1996 (1996-03-15), pages 1457-1465. |
|  | AJ | MENDELSOHN ET AL : "The EGF receptor family as targets for cancer therapy" oncogene, basingstoke, hants, GB, vol . 19, no. 56, 2000, pages 6550-6565. |

| | | | |
|-----------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 11/15/06 |
|-----------------------|---|-----------------|----------|

*EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.